296 related articles for article (PubMed ID: 25776466)
1. Optimal management of immune-related toxicities associated with checkpoint inhibitors in lung cancer.
Howell M; Lee R; Bowyer S; Fusi A; Lorigan P
Lung Cancer; 2015 May; 88(2):117-23. PubMed ID: 25776466
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint blocking antibodies in cancer immunotherapy.
Kyi C; Postow MA
FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
[TBL] [Abstract][Full Text] [Related]
3. Immune checkpoint inhibitors in lung cancer: past, present and future.
Seetharamu N; Budman DR; Sullivan KM
Future Oncol; 2016 May; 12(9):1151-63. PubMed ID: 27019997
[TBL] [Abstract][Full Text] [Related]
4. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors.
Langer CJ
Am J Clin Oncol; 2015 Aug; 38(4):422-30. PubMed ID: 24685885
[TBL] [Abstract][Full Text] [Related]
5. Current Perspectives in Immunotherapy for Non-Small Cell Lung Cancer.
Garon EB
Semin Oncol; 2015 Oct; 42 Suppl 2():S11-8. PubMed ID: 26477470
[TBL] [Abstract][Full Text] [Related]
6. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
Chow LQ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint therapy for non-small-cell lung cancer: an update.
Xia B; Herbst RS
Immunotherapy; 2016; 8(3):279-98. PubMed ID: 26860624
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 immune checkpoint blockade in non-small cell lung cancer.
Bagley SJ; Bauml JM; Langer CJ
Clin Adv Hematol Oncol; 2015 Oct; 13(10):676-83. PubMed ID: 27058572
[TBL] [Abstract][Full Text] [Related]
10. Drug of the year: programmed death-1 receptor/programmed death-1 ligand-1 receptor monoclonal antibodies.
Robert C; Soria JC; Eggermont AM
Eur J Cancer; 2013 Sep; 49(14):2968-71. PubMed ID: 23907003
[TBL] [Abstract][Full Text] [Related]
11. [Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment].
Passat T; Touchefeu Y; Gervois N; Jarry A; Bossard C; Bennouna J
Bull Cancer; 2018 Nov; 105(11):1033-1041. PubMed ID: 30244981
[TBL] [Abstract][Full Text] [Related]
12. Targeting the immune system to treat lung cancer: rationale and clinical experience.
Guibert N; Delaunay M; Mazières J
Ther Adv Respir Dis; 2015 Jun; 9(3):105-20. PubMed ID: 25827132
[TBL] [Abstract][Full Text] [Related]
13. [Recent Development of Therapies for Melanoma Using Immune Checkpoint Blockades].
Okuyama R
Gan To Kagaku Ryoho; 2016 Jun; 43(6):661-5. PubMed ID: 27306802
[TBL] [Abstract][Full Text] [Related]
14. Checkpoint inhibitors in Hodgkin's lymphoma.
Jezeršek Novaković B
Eur J Haematol; 2016 Apr; 96(4):335-43. PubMed ID: 26560962
[TBL] [Abstract][Full Text] [Related]
15. Enhanced expression of Programmed cell death 1 (PD-1) protein in benign vascular anomalies.
Amaya CN; Wians FH; Bryan BA; Torabi A
Pathology; 2017 Apr; 49(3):292-296. PubMed ID: 28238417
[TBL] [Abstract][Full Text] [Related]
16. Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy.
Hamid O; Carvajal RD
Expert Opin Biol Ther; 2013 Jun; 13(6):847-61. PubMed ID: 23421934
[TBL] [Abstract][Full Text] [Related]
17. [Era of cancer immunotherapy has come].
Nakatsura T
Nihon Rinsho Meneki Gakkai Kaishi; 2016; 39(3):164-71. PubMed ID: 27320931
[TBL] [Abstract][Full Text] [Related]
18. Emerging drugs targeting PD-1 and PD-L1: reality or hope?
Casaluce F; Sgambato A; Sacco PC; Palazzolo G; Maione P; Rossi A; Ciardiello F; Gridelli C
Expert Opin Emerg Drugs; 2014 Dec; 19(4):557-69. PubMed ID: 25253438
[TBL] [Abstract][Full Text] [Related]
19. CTLA-4 and PD-1/PD-L1 blockade: new immunotherapeutic modalities with durable clinical benefit in melanoma patients.
Ott PA; Hodi FS; Robert C
Clin Cancer Res; 2013 Oct; 19(19):5300-9. PubMed ID: 24089443
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy for gastric cancers: emerging role and future perspectives.
Bonotto M; Garattini SK; Basile D; Ongaro E; Fanotto V; Cattaneo M; Cortiula F; Iacono D; Cardellino GG; Pella N; Fasola G; Antonuzzo L; Silvestris N; Aprile G
Expert Rev Clin Pharmacol; 2017 Jun; 10(6):609-619. PubMed ID: 28349740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]